Overwhelming evidence indicates that the Aβ (amyloid β-peptide) plays a critical role in the pathogenesis of Alzheimer's disease. Aβ is derived from the APP (amyloid precursor protein) by the action of two aspartyl proteases (β-and γ -secretases) that are leading candidates for therapeutic intervention. APP is a member of a multigene family that includes APLP1 (amyloid precursor-like protein 1) and APLP2. Both APLPs are processed in a manner analogous to APP, with all three proteins subject to ectodomain shedding and subsequent cleavage by γ -secretase. Careful study of the APP family of proteins has already revealed important insights about APP. Here, we will review how knowledge of the similarities and differences between APP and the APLPs may prove useful for the development of novel disease-modifying therapeutics.
Introduction
Myriad converging lines of evidence suggest that progressive accumulation of Aβ (amyloid β-peptide) initiates a complex cascade of events leading to AD (Alzheimer's disease) [1] . Aβ is derived from the APP (amyloid precursor protein) by the sequential action of proteolytic activities designated β-and γ -secretases [2] [3] [4] and these proteases are targets for therapeutic intervention. However, rapidly emerging data indicate that these activities are important in the processing of numerous other proteins [5] [6] [7] . Consequently, an explicit understanding of the extent of the involvement of β-and γ -secretases in cellular processing and signalling pathways is necessary for the rational design of small molecules that will chronically inhibit one or another secretase to treat or prevent AD.
The APP family of proteins
APP is a type I transmembrane glycoprotein that has been identified in many vertebrate species and is a member of an evolutionarily conserved protein family [8, 9] . Searches for genes implicated in familial AD led to the identification of the mammalian homologues, APLP1 (amyloid precursor-like protein 1) [10] and APLP2 [11] . APP-like proteins have also been identified in Drosophila melanogaster (APPL) [12] and Caenorhabditis elegans (APL-1) [13] . All of the members of the APP-like gene family display impressive amino acid and domain homology to APP as well as to each other ( Figure 1 ). APP-like proteins are predicted to have a single membrane-spanning domain and a highly conserved cytoplasmic domain that contains an NPXY (Asn-Pro-Xaa-Tyr) clathrin internalization signal and putative phosphorylation sites. Identification of APP and APLP2, but not APLP1, in Xenopus laevis suggests the evolutionary occurrence of APP and pre-APLP lineages prior to the mammalian-amphibian split and indicates that the APLP1 gene diverged from the APLP2 gene and did not arise from the first gene duplication event [9] . The conspicuous absence of the Aβ sequence in the relevant region of the APLPs indicates that only APP can directly give rise to the main component of the amyloidcontaining senile plaques that characterize the disorder we know as AD. Like APP, APLP2 contains three exons that can be alternatively transcribed (Figure 1 ), but the APLP1 gene does not give rise to alternatively spliced exons [14] and, as in the case of APPL and APL-1 [13] , produces a single transcript. The overall conservation of amino acid sequence and domain structure, and the overlapping brain expression patterns of APP and the APLPs [11, 15] , strongly suggest that these polypeptides share similar biological roles.
What is the normal function of APP, APLP1 and APLP2?
On the basis of the old adage 'you never miss something until it is gone', several groups have created APP-or APLPdeficient mice to better understand the normal function of these proteins (e.g. [16, 17] ). Single disruptions of APP, APLP1 or APLP2 each cause minor abnormalities that are largely distinct for the different family members [16, 18] . Although the phenotypes of the single KO (knockout) mice are relatively mild, in vivo and in vitro studies suggest that APP, APLP1 and APLP2 function to promote neurite outgrowth, neural cell migration and copper homoeostasis [16, 17, [19] [20] [21] [22] and that the rather benign phenotypes seen in KO mice may result from functional redundancy between APP, 
APLP1 and APLP2. In contrast, APLP2
−/− /APP −/− mice and APLP2 −/− /APLP1 −/− mice each show a lethal phenotype (postnatal day 1), whereas APLP1 −/− /APP −/− mice are apparently normal [16] . These results provide genetic evidence for at least some distinct physiological roles for APP and APLP2 and suggest that APLP2 has the key physiological role among the family members. Curiously, no detectable gross or histopathological abnormalities were observed in any of these lines, whereas in triple KO mice (APLP2 −/− / APP −/− /APLP1 −/− ), which die in utero, 81% of animals showed cranial defects [21] . Cortical dysplasia resembling human type II lissencephaly was apparent in 68% of triple KO animals and partial loss of Cajal Retzius cells was evident at E18.5 (embryonic day 18.5). In agreement with this perturbation of neuronal migration, knock-down of APP expression in post-mitotic cells of the cortical ventricular zone by in utero electroporation with shRNA (small-hairpin RNA) hindered the migration of these cells, preventing their entrance into the cortical plate [22] . Importantly, this deficit was rescued by overexpression of APP, APLP1 or APLP2, demonstrating that all three proteins can function in neuronal migration during forebrain development.
Proteolytic processing of APP and the APLP proteins
Years of study have revealed that APP undergoes extensive post-translational modifications involving two related proteolytic pathways mediated by three distinct cleavage events. Both pathways are initiated by shedding of the large ectodomain ( Figure 2 ). α-Secretase cleaves APP between Lys 16 and Leu 17 of the Aβ domain [23] generating APPsα and C83. This cleavage is mediated by members of the ADAM (a disintegrin and metalloproteinase) family of proteases, the most relevant of which appear to be ADAM 10 and ADAM 17 [24] [25] [26] [27] . The α-secretase cleavage site appears to be determined by spatial constraints, with proteolysis occurring 12-13 amino acids from the plasma membrane [28] . In contrast, the cleavage leading to Aβ production is mediated by a single aspartyl protease with a loose, but primary sequence-based, substrate specificity [29] . BACE-1 (β-amyloid-cleaving enzyme-1; β-secretase) acts immediately N-terminal to the Aβ domain, simultaneously generating APPsβ and C99 (Figure 2) [30, 31] . BACE also cuts at a second, less-favoured, site 11 residues further C-terminal, producing C89 and a slightly longer APPsβ. All three CTFs (C-terminal fragments), C99, C89 and C83, serve as substrates for γ -secretase, a unique aspartyl protease, the active site of which is provided by PS (presenilin) [5] . But, unlike α-and β-cleavage, γ -secretase acts deep within the membrane and cleaves at multiple sites [32] . The two most prominent forms of Aβ and p3 terminate at Val 40 and Ala 42 [2] , whereas the concomitantly released ICDs (intracellular C-terminal domains) begin at sites some 9-10 amino acids downstream of these residues [33] . This discrepancy led to the realization that γ -secretase actually cleaves APP CTFs at three different positions. The first, referred to as the ε-site, occurs 9-10 residues C-terminal to the AβVal 40 position and gives rise to the 49-50-residuelong ICD [33, 34] . The second cleavage occurs six residues C-terminal to AβVal 40 and is referred to as the ζ -site [32, 35] . The final cut occurs at the γ -site and gives rise to Aβ 40 /Aβ 42 or p3 40 /p3 42 .
Until recently, the proteolytic processing of APLPs had received little attention. Early studies indicated that both APLP1 and APLP2 undergo extensive post-translational modification and that C-terminally truncated fragments can be detected in medium from cultured cells and in human cerebrospinal fluid [36] [37] [38] . The first hint that APLPs might be processed by γ -secretase came from the observation that a putative APLP1 CTF was elevated in brain from animals deficient in PS1 [39] . The assumption that APLPs are γ -secretase substrates received further support by the fortuitous detection of APLP ICDs that co-purified with rat brain membrane APP ICD [33] . Detection of elevated levels of APLP2 CTFs in brain lysates of PS1 KO mice and in cells stably expressing dominant-negative PS1 and PS2 mutants, together with the finding that γ -secretase inhibitors caused an accumulation of APLP1 and APLP2 CTFs [40, 41] , provide compelling evidence that both proteins are true γ -secretase substrates. In accord with this finding, SH-SY5Y and CHO (Chinese-hamster ovary) cells were found to produce and secrete peptides equivalent to Aβ and p3 in a γ -secretasedependent fashion [42, 43] . Cells expressing APLP1 secrete a ∼3.5 kDa peptide, which we refer to as APLP1 peptide (AP-1), and cells expressing APLP2 secrete two peptides of ∼4 and ∼5 kDa, which we have named AP-2a and AP-2b respectively [43] . β-Secretase inhibitors OM003-dr9 and Merck compound 3 completely blocked AP-2a production and significantly diminished production of AP-2b, whereas they had no effect on AP-1 production [43] . In agreement with these results, Eggert et al. [42] have shown that AP-1 production is diminished by treatment with ADAM inhibitors, thus suggesting that AP-1 is the product of consecutive α-and γ -cleavage, whereas AP-2a (and possibly AP-2b) is produced by the concerted action of both β-and γ -secretases.
Detection of AP-1 and AP-2 raises the question as to what other proof there is that APLPs are processed by BACE or α-secretase? For β-processing of APLP2 the evidence is substantial. Levels of soluble APLP2 are decreased in homogenates from BACE KO mouse brain and increased in homogenates from transgenic mice overexpressing BACE [44] . Similarly, in brain membrane extracts we have detected three APLP2 CTFs, the upper one of which is increased when BACE is transgenically overexpressed and decreased when BACE is ablated (C. Sala Frigerio, D.J. Selkoe and D.M. Walsh, unpublished work). Proof of α-processing of APLP2 is less definitive, but is supported by the fact that APLP2 has three CTFs only one of which is produced by BACE and by studies demonstrating that APLP2 secretion, like APPsα secretion, can be stimulated by activators of PKC (protein kinase C) and by overexpression of ADAM 10 [45] . Thus it seems that APLP2 undergoes processing in a manner highly similar to APP, serving as a substrate for α-, β-and γ -secretases. For APLP1 the situation is less certain. In cell culture, overexpression of BACE leads to increases in the levels of both APLP1 secretion and APLP1 CTF [46] , whereas in mouse brain neither genetic ablation nor overexpression significantly altered the single APLP1 CTF [47] . Similarly, in cells treated with BACE inhibitors, APLP1 CTF is unaffected [47] . Thus while BACE can cleave APLP1 in vitro it is unclear if it does so in vivo.
APLPs as novel targets for therapeutic intervention
Although neglected for many years, understanding the similarities and differences between APP and APLP1 and APLP2 is of significant therapeutic importance. Both in terms of avoiding possible side effects resulting from non-specific inhibition of γ -and/or β-secretase, and, as an alternative means of modulating amyloidogenic processing of APP, further study of APLP1 and APLP2 is warranted. Besides APP, APLP2 is the only other protein known to be processed by both β-and γ -secretases and given that APLP2 appears to play an important physiological role, the impact on APLP2 of inhibiting either enzyme should be carefully monitored. In terms of therapeutic design, analogous processing of APLP2 and APP offers not only possible problems, but possible solutions. Up-regulation of APLP2 (either at the transcriptional level or by stabilization of APLP2 protein) would provide a substrate that could compete with APP for β-and γ -secretase and hence reduce Aβ production. Similarly, since the cytoplasmic domains of APP, APLP1 and APLP2 are known to interact with adaptor proteins [41] that directly modulate APP processing [48] , competition between APP and the APLPs may also influence APP processing by competing for limiting quantities of adaptors. Indeed, it was recently demonstrated that overexpression of APLP1 or APLP2 decreased endocytosis of APP in a manner that was dependent on FE65 and the LDL (low-density lipoprotein)-receptor-related protein [49] and as a consequence increased α-processing of APP while decreasing β-cleavage [49] . An additional benefit of APLP2 up-regulation is the fact that APLP2 has been shown to compensate for the loss of APP in a variety of paradigms (e.g. where APP is knocked down or ablated). Thus, since it seems likely that the normal function of APP is (at least in part) mediated through its proteolytic products (e.g. APPsα/β), therapeutic up-regulation of APLP2 should increase corresponding APLP2 products and hence overcome the loss of beneficial APP products. Moreover, initial investigations revealed that the APLP peptides AP-1 and AP-2 do not readily aggregate or appear to influence Aβ aggregation [43] . Hence, if agents could be found to specifically up-regulate APLP levels, such an approach could offer a novel route for therapeutic intervention.
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